For Perspective on Bonuses I was last a pharma rep in

New Post Public Reply Private Reply Replies (1) Message Board
Respert24
626
For Perspective on Bonuses
I was last a pharma rep in 2012. A casualty of years of laying off reps that started around the time of the subprime mortgage bullshit tanking the global economy. I was just a primary care rep, having reset my position every couple years as moves to different companies or transfers out of state curtailed any momentum toward specialty of training roles I was interested in. Once out, it was hard to get back in because there were a ton of highly qualified reps who had been laid off over the previous 2-3 years trying to get back in. I moved over to medical device in a niche industry. Not a crazy OR-based Stryker kind of thing with 24h on call and crazy 400k income. It was just more standard devices used in medical environments that paid similarly to what I was doing in pharma. There I moved into government-focused sales and managed the east coast reps for a stretch. This is all important for what I tell you next.

In my role as what amounted to essentially an entry level pharma job, I was making around 80k salary and a bonus that would usually fall around 40-50% of base. Pretty common stuff at the time. I had worse bonus years and rarely better ones, because I was the lucky recipient of shitty territories over and over again where I couldn't physically get in front of most of my top prescribing docs. You might imagine that it's hard to convince someone to prescribe more of your drug if you can't even speak with them, and you'd be right. But even then I don't think I ever made less than 15k in bonus money during a full year, even in the shittiest of years in the shittiest of territories. Didn't Jay make a measly 30k the year before and everyone was still butthurt he'd get anything? 

If you do the math on what I made as a pharma rep FOURTEEN YEARS AGO and what Jay made in salary and bonus this past fiscal year, he's sitting at like 4-5x both the salary and the bonus of a primary care pharma rep circa 2012. Making his pay for what he does, in my opinion, is not excessive at all. 

In a world where there will be sales reps selling the drug that Jay ushered to market when all seemed potentially lost, Jay should absolutely be making 4-5x what those reps will be making. And I wouldn't be surprised to see my pay range from fourteen years ago be laughed at by current reps, especially specialty or hospital reps that call on oncologists. It's likely less than a 4-5x difference in 2026.

Finding research partners, designing and running trials, working within the FDA's terrible structure, fighting off the Adam F's of the world, overcoming the Pour Brothers dicking over the company/investors/drug, the two year hold, and on and on. That is all so much more difficult and important than the reps out selling a drug that will virtually sell itself. I'm not for CEOs making crazy multiples of lower level employees, but 4-5x is fine to me.

Then, in my last job as a manager in the med device company, before I struck out on my own over five years ago, I was making a salary of 125k with a bonus set at 40% of my salary (at 100% attainment). Again I never made less than 15k annually. And again, Jay making 4-5x those numbers is fair to me. He's leading a ton of really difficult and expensive work. And if we're honest with where we are today versus where we were when the hold was lifted, Jay and the team really have advanced LL and the company quite far.

Should it have happened faster? Sure.

Should it have made a dent in the shitty share price? Yes.

Does it suck to see the disconnect between rah-rah company bonuses and investors stuck around .20? Absolutely.

Is asking questions to yourself and answering them hackneyed? C'mon man, it's a Sunday. I've barely dipped into the caffeine. But also, yes.

I do think that disconnect between a bonus payout for performance while the share price continues to struggle is the main driver of everyone's frustration, and I'd argue there's a lot the company could have done better in regards to supporting the share price and keeping us informed. We're just a few months shy of finding out if Jay really did apply for BTD, but also if the FDA awards it. We're just about four months away seeing the fruits of their labor from the work they've been doing running Clover, and adding research partners, and opening new trials (Alz, I/Pre SPY, Kleos, Kasi, etc.), and lining up pharma partners, and possibly more. 

That's a lot of work even if we feel like it should have happened sooner.

Sometime during these next 1-4 months is when I expect the chasm to close, and all this anger over the bonuses to feel foolish. Because, in my humble opinion, it is. 

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Oatly’s $4.13 Tender Offer Is a Legal Detour, Not a Sale

Updated Category News Views 100

A $4.13 cash offer trading against a $7.17 close is the sort of thing that makes investors squint hard, and Verlinvest is practically waving a flag telling them why. This is not a conventional attempt to buy Oatly Group AB. It is a technical tender offer built to satisfy Swedish takeover rules while Verlinvest buys out its joint-venture partner’s interest in Oatly’s...

Continue Reading
Chicago Kertész Show Puts Photography's Quiet Giant First

Updated Category News Views 112

A fork, a plate, and a sharp eye can outlast plenty of louder art. Leica Gallery Chicago is putting that proposition on the wall with André Kertész: The Master, opening December 4, 2026 and running through January 17, 2027. More than thirty signature works is not a sprawling museum survey, and frankly that may be the point. Kertész did not need grand scale to make his...

Continue Reading
Greenberg Traurig Adds Privacy Muscle in Denver Office

Updated Category News Views 139

Privacy work used to be the legal department's back-room plumbing; now it can jam an entire product launch. That is why Greenberg Traurig's decision to bring Amber Mednick in as of counsel in Denver deserves more attention than the usual law-firm hiring blurb. This is not a splashy deal, and nobody should pretend one lateral hire rewrites the competitive map. Still, it is...

Continue Reading
CVS Puts Youth Soccer Stories on Its Store Shelves

Updated Category News Views 76

Two kids with real community ties just got a megaphone most grown-ups never receive. CVS Pharmacy has named Caroline, 9, of Holmes Beach, Florida, and Zoe, 12, of Los Angeles, as the first grand-prize winners of its Home Team Heroes youth soccer contest. Each player’s selected nonprofit soccer organization will receive a $25,000 grant, while their stories will appear on...

Continue Reading
Duetti, CesiumAstro, and a Busy NYSE Capital Morning

Updated Category News Views 94

Three very different piles of money are jamming up the November 20 NYSE slate, and that contrast is the whole point. Private music catalogs, space-and-defense communications, and a new stock-and-bond ETF do not belong in the same bucket. Yet all three are competing for investor attention before the opening bell, alongside Danaos Corporation's 20th listing anniversary....

Continue Reading
AMP Pushes Debt Wall to 2029 With €1.3B Green Notes

Updated Category News Views 108

A Refinancing With Some Actual Breathing Room Metal cans may be boring, but a debt wall arriving in 2028 is not—and Ardagh Metal Packaging has moved that problem down the road. AMP priced €1.3 billion of senior secured floating-rate green notes on November 20, 2026. The proceeds are earmarked to redeem $600 million of senior secured green notes due in 2028 and €450...

Continue Reading
Teachstone’s Bronze Award Puts Classroom Quality in Focus

Updated Category News Views 36

Small Classroom Moments Finally Get Their Due A child’s hesitant question can disappear in the noise of a busy classroom, which is precisely why Teachstone’s latest recognition deserves more than the usual polite golf clap. The Charlottesville-based Certified B Corporation received a Bronze Anthem Award for its “From Measurement to Momentum” initiative, in the...

Continue Reading
Shenzhen’s 50-Year Message Carries Real Trade Weight

Updated Category News Views 68

A city once framed as a frontier fishing village is being presented as China’s sharpest recent economic before-and-after picture. At the welcome dinner for the 33rd APEC Economic Leaders’ Meeting in Shenzhen, President Xi Jinping gave guests a compact geographic guide to China’s past: Xi’an for thousands of years, Beijing for 500 years, Shanghai for 100 years, and...

Continue Reading
MTI Adds Aviation Veterans as Acorn Builds MRO Plan

Updated Category News Views 127

Two old hands entering a boardroom can matter more than another glossy growth slogan, especially in aircraft maintenance, where a delayed part can ground an airplane and turn a customer relationship sour in a hurry. MTI Aviation has added Tony DiSimone Sr. and Aviv Tzur to its board, a move announced November 20, 2026, after Acorn Capital Management took a majority...

Continue Reading
Sprocket’s GigaOm Leap Puts PTaaS Claims Under Scrutiny

Updated Category News Views 65

Security vendors love a shiny quadrant, but this one deserves more than the usual polite golf clap. Sprocket Security moved from Challenger and Outperformer in GigaOm’s 2025 Penetration Testing as a Service assessment to a Leader in the version 5 report released in 2026. That is a meaningful jump in a category where buyers are tired of annual testing reports that go...

Continue Reading

Top 5 Most Recently Viewed Articles

Aluminum Design Fumble: Geometry Over Wall Thickness

Updated Category News Views 420

A Misstep in Aluminum Design Practices Well, here's a nugget of wisdom for the metal enthusiasts out there—stop beefing up aluminum components with thicker walls and focus on smart geometry. This isn't a drill, folks. Mark Coyle, a seasoned mind over at American Custom Metals, has been waving the flag for smarter aluminum design methods right from Rochester, NY, and...

Continue Reading
BW LPG Limited Welcomes BW Chinook: A Significant Milestone

Updated Category News Views 180

Significant Acquisition by BW LPG Limited BW LPG Limited has recently taken a remarkable step in enhancing its fleet and operational capabilities. The company announced the acquisition of the vessel BW Chinook, marking an important milestone in its ongoing strategy to strengthen its position in the global LPG market. Details of the Vessel Delivery Following a stock...

Continue Reading
COMAC's Expansion: New Hong Kong Office and Maintenance Deal

Updated Category News Views 175

COMAC's Global Expansion Efforts Chinese planemaker COMAC has taken a significant step in its quest to enter the global passenger jet market by inaugurating its second international office in Hong Kong. This move aligns with their strategy to provide enhanced services and establish a stronger footprint outside mainland China. The opening not only symbolizes growth but...

Continue Reading
Torrid Holdings CEO Lisa Harper Makes Strategic Stock Move

Updated Category News Views 415

Lisa Harper's Recent Sale of Company Shares Lisa Harper, the CEO of Torrid Holdings Inc. (NYSE: CURV), has recently sold shares worth $283,909, according to a filing with the Securities and Exchange Commission. In this transaction, she sold 74,713 shares at a price of $3.80 each. This sale is part of her exercise of the underwriters' option to purchase additional shares...

Continue Reading
Getty Images Plans Q3 2024 Financial Results Release Date

Updated Category News Views 102

Getty Images Announces Q3 2024 Financial Results Date Getty Images Holdings, Inc. (NYSE: GETY), a leader in the global visual content industry, is gearing up to share its financial results for the third quarter of 2024. The results will be unveiled right after market closing on November 7, 2024. This announcement signals an important moment for stakeholders keeping a...

Continue Reading